Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small integral membrane protein 11B (SMIM11B) is predicted to be a single-pass membrane protein, but it remains essentially uncharacterized and its function in human biology is unknown. There are no published data describing its roles as a receptor, enzyme, transporter, or other recognized therapeutic target class, nor any described disease associations, biological pathways, or drug interactions[2][7]. By standard gene nomenclature conventions, "SMIM11" and its variants (including SMIM11A and SMIM11B) are distinct genes related to the small integral membrane protein 11 family, but only SMIM11 (not SMIM11B) has moderate experimental characterization[1][3][5]. SMIM11B has not been definitively established as a therapeutic target or disease biomarker, and its molecular and functional properties require further investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small integral membrane protein 11B (SMIM11B).